D. Boral Capital Reiterates “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $31.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday. BTIG Research started coverage on shares of NRx Pharmaceuticals in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $18.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, March 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $28.50.

NRx Pharmaceuticals Trading Down 1.9 %

NASDAQ NRXP opened at $2.08 on Wednesday. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01. The firm has a market capitalization of $35.19 million, a PE ratio of -0.97 and a beta of 1.41. The business’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $2.10.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). As a group, analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at $56,000. Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals in the 4th quarter worth about $61,000. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after buying an additional 43,135 shares during the period. AdvisorShares Investments LLC increased its holdings in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares during the last quarter. Finally, Sassicaia Capital Advisers LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth about $33,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.